TWI354555B - Substituted spirobenzazepines - Google Patents

Substituted spirobenzazepines Download PDF

Info

Publication number
TWI354555B
TWI354555B TW093117253A TW93117253A TWI354555B TW I354555 B TWI354555 B TW I354555B TW 093117253 A TW093117253 A TW 093117253A TW 93117253 A TW93117253 A TW 93117253A TW I354555 B TWI354555 B TW I354555B
Authority
TW
Taiwan
Prior art keywords
spiro
benzo
compound
aza
carboxy
Prior art date
Application number
TW093117253A
Other languages
English (en)
Chinese (zh)
Other versions
TW200515911A (en
Inventor
Mona Patel
Philip J Rybczynski
Min Amy Xiang
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of TW200515911A publication Critical patent/TW200515911A/zh
Application granted granted Critical
Publication of TWI354555B publication Critical patent/TWI354555B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093117253A 2003-06-17 2004-06-16 Substituted spirobenzazepines TWI354555B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17

Publications (2)

Publication Number Publication Date
TW200515911A TW200515911A (en) 2005-05-16
TWI354555B true TWI354555B (en) 2011-12-21

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093117253A TWI354555B (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines

Country Status (30)

Country Link
US (2) US20040266752A1 (OSRAM)
EP (1) EP1633719B1 (OSRAM)
JP (1) JP5252614B2 (OSRAM)
KR (1) KR101086246B1 (OSRAM)
CN (1) CN100467454C (OSRAM)
AR (1) AR044782A1 (OSRAM)
AT (1) ATE444953T1 (OSRAM)
AU (1) AU2004281257C1 (OSRAM)
BR (1) BRPI0411598A (OSRAM)
CA (1) CA2529649C (OSRAM)
CL (1) CL2004001507A1 (OSRAM)
CR (1) CR8168A (OSRAM)
CY (1) CY1109585T1 (OSRAM)
DE (1) DE602004023501D1 (OSRAM)
DK (1) DK1633719T3 (OSRAM)
EA (1) EA011089B1 (OSRAM)
ES (1) ES2332724T3 (OSRAM)
HR (2) HRP20090606T1 (OSRAM)
IL (1) IL172630A (OSRAM)
ME (1) ME00320B (OSRAM)
NO (1) NO20060247L (OSRAM)
NZ (1) NZ544180A (OSRAM)
PL (1) PL1633719T3 (OSRAM)
PT (1) PT1633719E (OSRAM)
RS (1) RS20050930A (OSRAM)
SI (1) SI1633719T1 (OSRAM)
TW (1) TWI354555B (OSRAM)
UA (1) UA82236C2 (OSRAM)
WO (1) WO2005037795A2 (OSRAM)
ZA (1) ZA200600430B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0411652A (pt) * 2003-06-17 2006-08-08 Janssen Pharmaceutica Nv processo para a preparação de derivados de espirobenzoazepina substituìdos não-peptìdicos
WO2007084591A2 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
EP2078022B1 (en) * 2006-09-22 2011-11-09 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
EP2076517A1 (en) 2006-09-22 2009-07-08 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
CA2705097A1 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
US20150238502A1 (en) 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
CN104884436B (zh) 2012-12-26 2017-06-13 株式会社三和化学研究所 苯并氮杂衍生物及其医药用途
JP7607788B2 (ja) * 2021-03-05 2024-12-27 シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド 新規ベンズアゼピン縮合環式誘導体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
EP0663827A4 (en) * 1992-10-07 1995-11-15 Merck & Co Inc TOKOLYTIC OXYTOCINE RECEPTOR ANTAGONISTS.
US5512563A (en) * 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE10199068I2 (de) * 1994-04-22 2004-05-06 Pentech Pharmaceuticals Inc Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US7001898B2 (en) * 2000-07-05 2006-02-21 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
BRPI0411652A (pt) * 2003-06-17 2006-08-08 Janssen Pharmaceutica Nv processo para a preparação de derivados de espirobenzoazepina substituìdos não-peptìdicos

Also Published As

Publication number Publication date
CA2529649A1 (en) 2005-04-28
ZA200600430B (en) 2009-08-26
HRP20090606T1 (hr) 2010-01-31
CY1109585T1 (el) 2014-08-13
HRP20051006A2 (en) 2006-05-31
US7687494B2 (en) 2010-03-30
PL1633719T3 (pl) 2010-03-31
KR101086246B1 (ko) 2011-11-23
NZ544180A (en) 2009-01-31
EA011089B1 (ru) 2008-12-30
CA2529649C (en) 2012-01-31
EP1633719A2 (en) 2006-03-15
TW200515911A (en) 2005-05-16
AU2004281257A1 (en) 2005-04-28
DE602004023501D1 (de) 2009-11-19
AU2004281257C1 (en) 2010-07-01
ME00320B (me) 2011-05-10
RS20050930A (sr) 2008-04-04
CN1835925A (zh) 2006-09-20
PT1633719E (pt) 2009-11-11
US20040266752A1 (en) 2004-12-30
MEP49108A (en) 2011-02-10
IL172630A (en) 2011-10-31
DK1633719T3 (da) 2010-01-04
ES2332724T3 (es) 2010-02-11
CL2004001507A1 (es) 2005-05-27
US20070179128A1 (en) 2007-08-02
EA200501831A1 (ru) 2006-06-30
ATE444953T1 (de) 2009-10-15
BRPI0411598A (pt) 2006-08-29
EP1633719B1 (en) 2009-10-07
IL172630A0 (en) 2006-04-10
UA82236C2 (en) 2008-03-25
SI1633719T1 (sl) 2010-01-29
JP5252614B2 (ja) 2013-07-31
WO2005037795A3 (en) 2005-07-28
WO2005037795A2 (en) 2005-04-28
JP2007521272A (ja) 2007-08-02
NO20060247L (no) 2006-03-13
AU2004281257B2 (en) 2010-02-04
AR044782A1 (es) 2005-10-05
KR20060023157A (ko) 2006-03-13
CN100467454C (zh) 2009-03-11
CR8168A (es) 2008-09-10

Similar Documents

Publication Publication Date Title
ES2197945T3 (es) Compuestos activos en nuevos sitios de los canales de calcio activados por receptores utiles para el tratamiento de trastornos neurologicos.
CN101384261B (zh) 治疗疼痛的组合物
CN1805938B (zh) 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
TWI300064B (en) New neuropeptide y y5 receptor antagonists
Ong et al. Clinical potential of GABAB receptor modulators
TW200803862A (en) Compounds for modulating TRPV3 function
JP6977024B2 (ja) 5−ht2c受容体アゴニストおよび組成物ならびに使用方法
US10392390B2 (en) 5-HT2C receptor agonists and compositions and methods of use
TW201204724A (en) Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine derivatives
JP2021120379A (ja) 睡眠障害の治療及び予防
CA2476896A1 (en) Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
TWI354555B (en) Substituted spirobenzazepines
TW200901986A (en) New combination
TW200400186A (en) (S)-4-Amino-5-chloro-2-methoxy-N-[1-[1-[2-tetrahydrofuryl-carbonyl]-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof , pharmaceutical composition containing the same , and intermediate therefor
TW200418846A (en) Substituted benzoxazinones and uses thereof
TWI236469B (en) Diamine compound with condensed-ring groups
JPH0770013A (ja) β3 −アドレナリン作動薬として作用する{(7S)−7−[(2R)−2−(3−クロロフェニル)−2−ヒドロキシエチルアミノ]−5,6,7,8−テトラヒドロナフタレン−2−イルオキシ)酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
CN101084205A (zh) 作为5ht2c受体调节剂以治疗与其相关病症的n-联芳基和n-芳基杂芳基哌嗪衍生物
TW200902083A (en) Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine
TW200528433A (en) Novel compounds
JP2001199884A (ja) 鎮痛作用剤
US11613547B2 (en) G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment
TWI264436B (en) Phenyl-substituted imidazopyridines
JPH04500811A (ja) ムスカリン様物質レセプター拮抗薬
US10377763B2 (en) Morphinan derivative and medical usage thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees